Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
CDK9 is the kinase subunit of positive transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation. Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due t...
Main Authors: | Huasong Lu, Yuhua Xue, Guoying K Yu, Carolina Arias, Julie Lin, Susan Fong, Michel Faure, Ben Weisburd, Xiaodan Ji, Alexandre Mercier, James Sutton, Kunxin Luo, Zhenhai Gao, Qiang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2015-06-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/06535 |
Similar Items
-
Targeting CDK9 for Anti-Cancer Therapeutics
by: Ranadip Mandal, et al.
Published: (2021-05-01) -
Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors
by: Khayal Gasimli, et al.
Published: (2023-12-01) -
CDK9-dependent RNA polymerase II pausing controls transcription initiation
by: Saskia Gressel, et al.
Published: (2017-10-01) -
Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery
by: Ryan D. Martin, et al.
Published: (2020-05-01) -
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
by: Mei Zeng, et al.
Published: (2018-11-01)